Satoshi Kamidani

Infectious Disease

2015 Upper Gate Dr NE Rm 534
Atlanta, GA 30322

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

Effectiveness of Oseltamivir in Hospitalized Children With Laboratory-Confirmed Influenza, 2014-2023.

Effectiveness of Oseltamivir in Hospitalized Children With Laboratory-Confirmed Influenza, 2014-2023.

Journal: JAMA pediatrics

Published: August 10, 2026

Characteristics of Young Children Hospitalized With Acute Respiratory Failure From Infection With Respiratory Syncytial Virus, SARS-CoV-2, or Both, November 2023-March 2024.

Characteristics of Young Children Hospitalized With Acute Respiratory Failure From Infection With Respiratory Syncytial Virus, SARS-CoV-2, or Both, November 2023-March 2024.

Journal: Open forum infectious diseases

Published: January 05, 2026

Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025.

Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025.

Journal: MMWR. Morbidity and mortality weekly report

Published: December 05, 2025

mRNA COVID-19 Vaccine Effectiveness Against Severe Outcomes Among Adults Hospitalized with COVID-19 from May 2021 to January 2023.

mRNA COVID-19 Vaccine Effectiveness Against Severe Outcomes Among Adults Hospitalized with COVID-19 from May 2021 to January 2023.

Journal: Vaccines

Published: November 10, 2025

The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances.

The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances.

Journal: Vaccine

Published: October 31, 2025

Respiratory Syncytial Virus Hospitalizations in Adults ≥50 Years of Age and Those With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations, 2018-2020.

Respiratory Syncytial Virus Hospitalizations in Adults ≥50 Years of Age and Those With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations, 2018-2020.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: September 21, 2025

Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial.

Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial.

Journal: Vaccine

Published: February 17, 2025

Viral Etiologies of Acute Respiratory Illness in Older Adults and of Congestive Heart Failure and Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization During 2 Prepandemic Respiratory Seasons.

Viral Etiologies of Acute Respiratory Illness in Older Adults and of Congestive Heart Failure and Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization During 2 Prepandemic Respiratory Seasons.

Journal: Open forum infectious diseases

Published: February 13, 2025

A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose.

A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose.

Journal: NPJ vaccines

Published: September 16, 2024

Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.

Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.

Journal: Nature communications

Published: July 19, 2024

Adverse Event Following Immunization Monitoring System in Japan.

Adverse Event Following Immunization Monitoring System in Japan.

Journal: The Pediatric infectious disease journal

Published: May 17, 2024

Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.

Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: May 06, 2024

Showing 1-12 of 54

Last Updated: 09/26/2026